Maryland Vioxx Lawsuit Lawyers
Baltimore Celebrex Side Effects Attorneys

On December 23, 2005, the FDA issued a public health advisory regarding the use of non-steroidal anti-inflammatory drug products (NSAIDS), including those known as COX-2 selective agents. This announcement was made in response to recently released data showing that the COX-2 selective agents, such as Vioxx and Celebrex, may be associated with an increased risk of serious cardiovascular events, including heart attack and stroke.

Vioxx was voluntarily withdrawn from the market in September of 2004 by Merck & Co., Inc., due to its dangerous and possibly deadly side effects. Vioxx is used by more than two million people worldwide to treat arthritis, menstrual pain, and other medical conditions.

More than 27 million people have taken the prescription drug Celebrex, manufactured by Pfizer, since it was approved by the Food and Drug Administration on December 31, 1998. Celebrex is prescribed to treat arthritis pain, menstrual cramps, osteoarthritis, adult rheumatoid arthritis, inflammation, and other types of serious pain, but recently there have been questions as to whether Celebrex causes a higher risk of heart attacks and strokes in patients.

Our Maryland Vioxx and Celebrex Lawyers have experience in all areas of personal injury litigation law. We are located in Maryland and have offices in the metropolitan area of Washington, D.C. for your convenience. Our personal injury lawyers have excellent legal knowledge, financial resources, and superior negotiating skills. If you or a loved one has suffered serious side effects associated with taking the prescription drugs Vioxx or Celebrex, you should contact a Maryland lawyer at our law firm today to discuss your case.

If you or a loved one has suffered serious side effects from taking Celebrex or Vioxx, contact a Maryland attorney at our office today for a free consultation.

You may be able to sue for damages including:

• Physical pain and suffering, mental anguish and physical impairment;
• Medical expenses associated with the allegedly defective product; and
• Loss of earnings and/or earning capacity.